CN106413733A - 包含咪唑二肽的试剂 - Google Patents

包含咪唑二肽的试剂 Download PDF

Info

Publication number
CN106413733A
CN106413733A CN201580017212.3A CN201580017212A CN106413733A CN 106413733 A CN106413733 A CN 106413733A CN 201580017212 A CN201580017212 A CN 201580017212A CN 106413733 A CN106413733 A CN 106413733A
Authority
CN
China
Prior art keywords
group
genes
agent
aging
metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580017212.3A
Other languages
English (en)
Chinese (zh)
Inventor
久恒辰博
户塚护
萨秀夫
金子顺
片仓喜范
佐藤三佳子
松本贵之
森松文毅
今林悦子
松田博史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyushu University NUC
National Center of Neurology and Psychiatry
University of Tokyo NUC
NH Foods Ltd
Original Assignee
Kyushu University NUC
Nippon Meat Packers Inc
National Center of Neurology and Psychiatry
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University NUC, Nippon Meat Packers Inc, National Center of Neurology and Psychiatry, University of Tokyo NUC filed Critical Kyushu University NUC
Publication of CN106413733A publication Critical patent/CN106413733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/13—Dipeptidases (3.4.13)
    • C12Y304/1302—Beta-Ala-His dipeptidase (3.4.13.20)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8103—Exopeptidase (E.C. 3.4.11-19) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
CN201580017212.3A 2014-03-28 2015-03-04 包含咪唑二肽的试剂 Pending CN106413733A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014-069103 2014-03-28
JP2014069103 2014-03-28
JP2014142910A JP2015193582A (ja) 2014-03-28 2014-07-11 イミダゾールジペプチドを含む剤
JP2014-142910 2014-07-11
PCT/JP2015/056412 WO2015146522A1 (ja) 2014-03-28 2015-03-04 イミダゾールジペプチドを含む剤

Publications (1)

Publication Number Publication Date
CN106413733A true CN106413733A (zh) 2017-02-15

Family

ID=54195052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580017212.3A Pending CN106413733A (zh) 2014-03-28 2015-03-04 包含咪唑二肽的试剂

Country Status (8)

Country Link
US (2) US20170165314A1 (enExample)
EP (1) EP3124034B1 (enExample)
JP (1) JP2015193582A (enExample)
KR (2) KR20160146760A (enExample)
CN (1) CN106413733A (enExample)
ES (1) ES2879329T3 (enExample)
SG (2) SG11201608027RA (enExample)
WO (1) WO2015146522A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801737B (zh) * 2019-07-17 2023-05-11 日商東海物產股份有限公司 輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法
KR20230087856A (ko) * 2021-12-10 2023-06-19 교촌 에프 앤 비(주) 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법
TWI864035B (zh) * 2019-12-27 2024-12-01 日商三得利控股股份有限公司 含有環形二肽、嘌呤核苷及／或胺基酸、及雞萃取物之組成物、產製彼之方法、及環形二肽、嘌呤核苷及／或胺基酸、及雞萃取物之用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6401028B2 (ja) * 2014-11-27 2018-10-03 Ｓｈｉｏｄａライフサイエンス株式会社 鯨筋肉抽出物からなる中長期記憶障害予防改善剤
JP6550357B2 (ja) * 2016-08-24 2019-07-24 日本ハム株式会社 イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤
JP7134607B2 (ja) * 2016-08-25 2022-09-12 大正製薬株式会社 錠剤
JP6510004B2 (ja) * 2016-11-15 2019-05-08 日本ハム株式会社 イミダゾールジペプチドを含有するエクソソーム調節剤、およびエクソソームを含有する神経細胞活性化剤
JP2018140958A (ja) * 2017-02-28 2018-09-13 国立大学法人 東京大学 ペリサイトの変成を抑制する剤
US11148118B2 (en) * 2017-10-13 2021-10-19 W.M. Barr & Company, Inc. Encapsulated fragrance in compressed tablet
JP7251036B2 (ja) * 2018-06-28 2023-04-04 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
WO2020085459A1 (ja) * 2018-10-26 2020-04-30 国立大学法人東京大学 抗酸化剤、抗糖化剤又は抗炎症剤
JP7523771B2 (ja) * 2020-02-26 2024-07-29 国立大学法人 東京大学 トランジスタ型センサ
EP4338267A4 (en) * 2021-05-14 2025-01-08 University of Rochester Variants of sirt6 for use in preventing and/or treating age-related diseases
WO2025104978A1 (ja) * 2023-11-13 2025-05-22 国立大学法人 東京大学 ネクロプトーシス制御剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157835A1 (en) * 1994-09-09 1996-03-10 Masami Harada Hemopoietic function-stimulating agent
WO2003013514A1 (en) * 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
EP1285654A1 (en) * 2001-03-16 2003-02-26 Suntory Limited Autonomic controlling agents and health drinks and foods
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327404A1 (en) * 1994-11-08 2011-06-01 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
JP2000116987A (ja) 1998-10-15 2000-04-25 Sanyo Electric Co Ltd 洗剤溶かし装置およびこれを備えた洗濯機ならびに静止型溶解装置
JP4023648B2 (ja) 1999-01-13 2007-12-19 日本ハム株式会社 皮膚代謝促進物及び機能性食品
CA2389623A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
KR20020044740A (ko) * 2000-12-06 2002-06-19 강경선 카노신을 유효성분으로 하는 세포예정사 관련 질환의 예방및 치료제
US6498498B1 (en) * 2001-06-27 2002-12-24 Intel Corporation Apparatus and method for applying reciprocity to frequency-domain noise analysis
JP2007070316A (ja) 2005-09-09 2007-03-22 Nippon Meat Packers Inc 経口用組成物及び栄養補助食品
JPWO2007116987A1 (ja) * 2006-03-31 2009-08-20 日本ハム株式会社 学習機能向上効果及び抗不安効果を有する機能性食品及び薬剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157835A1 (en) * 1994-09-09 1996-03-10 Masami Harada Hemopoietic function-stimulating agent
EP1285654A1 (en) * 2001-03-16 2003-02-26 Suntory Limited Autonomic controlling agents and health drinks and foods
WO2003013514A1 (en) * 2001-08-08 2003-02-20 Carn-Aware Llc Improving neurological functions
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
V CALABRESE等: "Protective Effect of Carnosine During Nitrosative Stress in Astroglial Cell Cultures", 《NEUROCHEM RES》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801737B (zh) * 2019-07-17 2023-05-11 日商東海物產股份有限公司 輕度認知障礙改善用組成物及使用該組成物之輕度認知障礙的改善方法
TWI864035B (zh) * 2019-12-27 2024-12-01 日商三得利控股股份有限公司 含有環形二肽、嘌呤核苷及／或胺基酸、及雞萃取物之組成物、產製彼之方法、及環形二肽、嘌呤核苷及／或胺基酸、及雞萃取物之用途
KR20230087856A (ko) * 2021-12-10 2023-06-19 교촌 에프 앤 비(주) 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법
KR102868976B1 (ko) * 2021-12-10 2025-11-03 (주)잇마플 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법

Also Published As

Publication number Publication date
EP3124034A4 (en) 2018-03-21
WO2015146522A1 (ja) 2015-10-01
SG11201608027RA (en) 2016-11-29
KR20160146760A (ko) 2016-12-21
KR20220164079A (ko) 2022-12-12
ES2879329T3 (es) 2021-11-22
US20180140655A1 (en) 2018-05-24
EP3124034A1 (en) 2017-02-01
JP2015193582A (ja) 2015-11-05
EP3124034B1 (en) 2021-04-21
US20170165314A1 (en) 2017-06-15
SG10201808208PA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
EP3124034B1 (en) Imidazole dipeptide for treating dementia due to aging or cerebral atrophy
Boutrou et al. Sequential release of milk protein–derived bioactive peptides in the jejunum in healthy humans1234
JP6403039B2 (ja) Ｓｉｒｔ３およびｓｉｒｔ６の活性化剤
US20110178005A1 (en) Compositions and methods for treating disorders associated with overweight animals
Mizoguchi et al. Nutrigenomic studies of effects of Chlorella on subjects with high-risk factors for lifestyle-related disease
KR20090003263A (ko) 포유동물에서 건강 상태를 증진시키기 위한 레스베라트롤 및 그의 유도체의 용도
CN106456633A (zh) 糖代谢改善剂
JP2022118233A (ja) イミダゾールジペプチドを含む剤
Lee et al. The animal protein hydrolysate attenuates sarcopenia via the muscle-gut axis in aged mice
US20120258183A1 (en) Macronutrient sensitivity
Chen et al. Promoting neurogenesis in hippocampal dentate gyrus of chronic unpredictable stress-induced depressive-like rats with paeoniflorin
JP6510004B2 (ja) イミダゾールジペプチドを含有するエクソソーム調節剤、およびエクソソームを含有する神経細胞活性化剤
Almanza-Aguilera et al. Transcriptional response to a Mediterranean diet intervention exerts a modulatory effect on neuroinflammation signaling pathway
CN101389321A (zh) 白藜芦醇及其衍生物用于改善哺乳动物健壮状态的用途
CN114302718A (zh) 线粒体功能活化剂
CN118338897A (zh) 使用氨基酸共混物用于在动物中提供健康益处的组合物和方法
Famakin et al. A new role for downstream Toll-like receptor signaling in mediating immediate early gene expression during focal cerebral ischemia
Karlic et al. Vegetarian diet affects genes of oxidative metabolism and collagen synthesis
JP6550357B2 (ja) イミダゾールジペプチドを含有する、グリア細胞における神経栄養因子等の遺伝子の発現誘導剤
Segú et al. Intestinal taste receptor expression and its implications for health: an integrative analysis in female rats after chronic insect supplementation
US20250313905A1 (en) Methods and compositions for improved psychological and resilience measures
Doyle Case Report: Utilization of Urinary Neurotransmitter Metabolite Testing and Natural Supplements in the Management of Disordered Eating.
Wight The Effects of Severe Food Restriction and Post-Recovery on the Gut Microbiome
Hadjikyriakou et al. Nutrition, the Immune and Inflammatory Systems, and Mental Illness: What Is the Interplay?
Larkin et al. Gluten-free fish? Marine carnivores cobia (Rachycentron canadum) and European sea bass (Dicentrarchus labrax) have different tolerances to dietary wheat gluten

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination